Opus Genetics, Inc. (NasdaqCM: IRD)
Health Care · Biotechnology · US
$4.46
+1.13% today · +117.6% 1Y
Opus Genetics, Inc. (NasdaqCM: IRD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $371.05M and employs 28 people.
Over the last twelve months the share price has gained 117.6%, trading between 1.70 and 7.07.
Tweenvest scores Opus Genetics, Inc. across four factors: quality 43/100, value 59/100. Its strongest factor is value.
IRD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $371.05M
- Revenue (TTM)
- $9.86M
- P/E
- —
- EPS
- -1.29
- Dividend yield
- —
- Beta (5Y)
- 0.62
- 52-week high
- $7.07
- 52-week low
- $1.70
- Avg volume (3M)
- —
- Shares outstanding
- 83.20M
- Employees
- 28
- Next earnings
- —
About Opus Genetics, Inc.
Opus Genetics, Inc. is a clinical-stage biopharmaceutical company focused on ophthalmology. The company is dedicated to discovering and commercializing innovative therapies to address significant unmet medical needs in patients suffering from refractive and retinal eye disorders. Its portfolio includes Phentolamine Ophthalmic Solution, currently used to reverse pharmacologically induced mydriasis (pupil dilation). This solution is also advancing through Phase III clinical trials for the treatment of presbyopia and impaired vision in dim light or at night. A leading candidate in its retinal pipeline is APX3330, a small-molecule inhibitor targeting the reduction oxidation effector factor-1 protein. APX3330 has successfully completed Phase II clinical trials for diabetic retinopathy. Furthermore, Opus Genetics is developing APX2009 and APX2014, two preclinical product candidates also aimed at various retinal indications. Originally founded in 2018 as Ocuphire Pharma, Inc., the company maintains its headquarters in Farmington Hills, Michigan.
- ISIN
- US67577R1023
- Founded
- 2018
- Listed since
- Jan 19, 2015
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Kyverna Therapeutics, Inc.NasdaqGS: KYTX | $382.19M | $6.18 | +0.16% |
| vTv Therapeutics Inc.NasdaqCM: VTVT | $379.82M | $30.08 | -1.60% |
| Prelude Therapeutics IncorporatedNasdaqGS: PRLD | $377.99M | $3.88 | +5.72% |
| Heartseed Inc.TSE: 219A | $374.34M | ¥2,579.00 | -4.38% |
| Arcturus Therapeutics Holdings Inc.NasdaqGM: ARCT | $370.35M | $12.87 | -1.23% |
| Jiangsu CoWin Biotech Co., Ltd.SHSE: 688426 | $370.06M | CN¥22.58 | +2.82% |
| BioDlink International Company LimitedSEHK: 1875 | $366.35M | HK$3.72 | -3.38% |
| Inhibikase Therapeutics, Inc.NasdaqCM: IKT | $364.15M | $1.91 | -4.50% |
Figures last refreshed Oct 4, 2026.